let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer
Cited by 28
Related Papers
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183
Expert consensus on treatment for stage III non‐small cell lung cancer
|Medicine Advances|2023|18
MicroRNA-1288 promotes cell proliferation of human glioblastoma cells by repressing ubiquitin carboxyl-terminal hydrolase CYLD expression
|Molecular Medicine Reports|2017|6
CIAdex: Single-Cell FTIR Spectral Fingerprinting for Cell Identity Verification and Aging Quantification in Therapeutic Cell Manufacturing
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0